Household & Personal Products
Compare Stocks
2 / 10Stock Comparison
UG vs CBT
Revenue, margins, valuation, and 5-year total return — side by side.
Chemicals - Specialty
UG vs CBT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Household & Personal Products | Chemicals - Specialty |
| Market Cap | $32M | $4.24B |
| Revenue (TTM) | $11M | $3.58B |
| Net Income (TTM) | $2M | $285M |
| Gross Margin | 47.7% | 24.8% |
| Operating Margin | 21.3% | 15.7% |
| Forward P/E | 15.2x | 13.0x |
| Total Debt | $0.00 | $1.22B |
| Cash & Equiv. | $1M | $258M |
UG vs CBT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| United-Guardian, In… (UG) | 100 | 44.4 | -55.6% |
| Cabot Corporation (CBT) | 100 | 227.5 | +127.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: UG vs CBT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
UG carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 2 yrs, beta 0.33, yield 8.6%
- Lower volatility, beta 0.33, current ratio 7.31x
- Beta 0.33, yield 8.6%, current ratio 7.31x
CBT is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth -7.0%, EPS growth -10.4%, 3Y rev CAGR -4.9%
- 115.7% 10Y total return vs UG's -12.1%
- -7.0% revenue growth vs UG's -13.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -7.0% revenue growth vs UG's -13.4% | |
| Value | Lower P/E (13.0x vs 15.2x) | |
| Quality / Margins | 20.0% margin vs CBT's 8.0% | |
| Stability / Safety | Beta 0.33 vs CBT's 0.78 | |
| Dividends | 8.6% yield, 2-year raise streak, vs CBT's 2.2% | |
| Momentum (1Y) | +13.8% vs UG's -6.0% | |
| Efficiency (ROA) | 16.3% ROA vs CBT's 7.4%, ROIC 16.8% vs 17.4% |
UG vs CBT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
UG vs CBT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
UG leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CBT is the larger business by revenue, generating $3.6B annually — 339.0x UG's $11M. UG is the more profitable business, keeping 20.0% of every revenue dollar as net income compared to CBT's 8.0%. On growth, UG holds the edge at +19.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $11M | $3.6B |
| EBITDAEarnings before interest/tax | $2M | $731M |
| Net IncomeAfter-tax profit | $2M | $285M |
| Free Cash FlowCash after capex | $2M | $459M |
| Gross MarginGross profit ÷ Revenue | +47.7% | +24.8% |
| Operating MarginEBIT ÷ Revenue | +21.3% | +15.7% |
| Net MarginNet income ÷ Revenue | +20.0% | +8.0% |
| FCF MarginFCF ÷ Revenue | +18.1% | +12.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +19.6% | -3.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +27.3% | -23.1% |
Valuation Metrics
CBT leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
At 13.5x trailing earnings, CBT trades at a 11% valuation discount to UG's 15.2x P/E. On an enterprise value basis, CBT's 6.7x EV/EBITDA is more attractive than UG's 13.1x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $32M | $4.2B |
| Enterprise ValueMkt cap + debt − cash | $31M | $5.2B |
| Trailing P/EPrice ÷ TTM EPS | 15.22x | 13.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 13.04x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 13.14x | 6.71x |
| Price / SalesMarket cap ÷ Revenue | 3.05x | 1.14x |
| Price / BookPrice ÷ Book value/share | 2.86x | 2.58x |
| Price / FCFMarket cap ÷ FCF | 16.86x | 10.86x |
Profitability & Efficiency
UG leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
UG delivers a 19.1% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $17 for CBT. On the Piotroski fundamental quality scale (0–9), CBT scores 6/9 vs UG's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +19.1% | +16.8% |
| ROA (TTM)Return on assets | +16.3% | +7.4% |
| ROICReturn on invested capital | +16.8% | +17.4% |
| ROCEReturn on capital employed | +18.9% | +21.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | — | 0.71x |
| Net DebtTotal debt minus cash | -$1M | $957M |
| Cash & Equiv.Liquid assets | $1M | $258M |
| Total DebtShort + long-term debt | $0 | $1.2B |
| Interest CoverageEBIT ÷ Interest expense | — | 14.72x |
Total Returns (Dividends Reinvested)
CBT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CBT five years ago would be worth $14,321 today (with dividends reinvested), compared to $7,000 for UG. Over the past 12 months, CBT leads with a +13.8% total return vs UG's -6.0%. The 3-year compound annual growth rate (CAGR) favors CBT at 7.0% vs UG's -5.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +18.3% | +21.9% |
| 1-Year ReturnPast 12 months | -6.0% | +13.8% |
| 3-Year ReturnCumulative with dividends | -15.4% | +22.5% |
| 5-Year ReturnCumulative with dividends | -30.0% | +43.2% |
| 10-Year ReturnCumulative with dividends | -12.1% | +115.7% |
| CAGR (3Y)Annualised 3-year return | -5.4% | +7.0% |
Risk & Volatility
Evenly matched — UG and CBT each lead in 1 of 2 comparable metrics.
Risk & Volatility
UG is the less volatile stock with a 0.33 beta — it tends to amplify market swings less than CBT's 0.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CBT currently trades 96.1% from its 52-week high vs UG's 70.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.33x | 0.78x |
| 52-Week HighHighest price in past year | $9.88 | $84.60 |
| 52-Week LowLowest price in past year | $5.58 | $58.33 |
| % of 52W HighCurrent price vs 52-week peak | +70.9% | +96.1% |
| RSI (14)Momentum oscillator 0–100 | 46.2 | 71.7 |
| Avg Volume (50D)Average daily shares traded | 4K | 374K |
Analyst Outlook
Evenly matched — UG and CBT each lead in 1 of 2 comparable metrics.
Analyst Outlook
For income investors, UG offers the higher dividend yield at 8.60% vs CBT's 2.18%.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $78.00 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | +8.6% | +2.2% |
| Dividend StreakConsecutive years of raises | 2 | 4 |
| Dividend / ShareAnnual DPS | $0.60 | $1.77 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.0% |
UG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CBT leads in 2 (Valuation Metrics, Total Returns). 2 tied.
UG vs CBT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is UG or CBT a better buy right now?
For growth investors, Cabot Corporation (CBT) is the stronger pick with -7.
0% revenue growth year-over-year, versus -13. 4% for United-Guardian, Inc. (UG). Cabot Corporation (CBT) offers the better valuation at 13. 5x trailing P/E (13. 0x forward), making it the more compelling value choice. Analysts rate Cabot Corporation (CBT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — UG or CBT?
On trailing P/E, Cabot Corporation (CBT) is the cheapest at 13.
5x versus United-Guardian, Inc. at 15. 2x.
03Which is the better long-term investment — UG or CBT?
Over the past 5 years, Cabot Corporation (CBT) delivered a total return of +43.
2%, compared to -30. 0% for United-Guardian, Inc. (UG). Over 10 years, the gap is even starker: CBT returned +115. 7% versus UG's -12. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — UG or CBT?
By beta (market sensitivity over 5 years), United-Guardian, Inc.
(UG) is the lower-risk stock at 0. 33β versus Cabot Corporation's 0. 78β — meaning CBT is approximately 136% more volatile than UG relative to the S&P 500.
05Which is growing faster — UG or CBT?
By revenue growth (latest reported year), Cabot Corporation (CBT) is pulling ahead at -7.
0% versus -13. 4% for United-Guardian, Inc. (UG). On earnings-per-share growth, the picture is similar: Cabot Corporation grew EPS -10. 4% year-over-year, compared to -35. 2% for United-Guardian, Inc.. Over a 3-year CAGR, CBT leads at -4. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — UG or CBT?
United-Guardian, Inc.
(UG) is the more profitable company, earning 20. 0% net margin versus 8. 9% for Cabot Corporation — meaning it keeps 20. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UG leads at 21. 3% versus 16. 7% for CBT. At the gross margin level — before operating expenses — UG leads at 47. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Which pays a better dividend — UG or CBT?
All stocks in this comparison pay dividends.
United-Guardian, Inc. (UG) offers the highest yield at 8. 6%, versus 2. 2% for Cabot Corporation (CBT).
08Is UG or CBT better for a retirement portfolio?
For long-horizon retirement investors, United-Guardian, Inc.
(UG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 33), 8. 6% yield). Both have compounded well over 10 years (UG: -12. 1%, CBT: +115. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between UG and CBT?
These companies operate in different sectors (UG (Consumer Defensive) and CBT (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.